Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.

Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.

Abstract: The present invention relates to a method of preparing poly(acrylonitrile) fibers comprising: (i) providing a solution of poly(acrylonitrile) and a polyazide compound; and (ii) electrospinning the solution of poly(acrylonitrile) and a polyazide compound to provide fibers. The poly(acrylonitrile) fibers which are obtainable by the method are also claimed.

Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.

Abstract: Disclosed herein are prepregs for ceramic matrix composites, processes for the preparation of a green bodies using the prepregs disclosed herein, and processes for the preparation of the ceramic matrix composites from the green bodies prepared according processes provided herein.

Abstract: The invention concerns an electrically conductive non-woven fabric which fabric comprises or consists of a three-dimensional network of non-woven non-electrically conductive synthetic nanofibers and electrically conductive metal nanowires distributed therein, wherein the synthetic nanofibers comprise or consist of fibers having a diameter in the range of 10 nm to 2000 nm and a maximal length of 6 mm, wherein the electrically conductive metal nanowires comprise or consist of strands having a diameter in the range of 10 nm to 800 nm and a length in the range of 1 ?m to 500 ?m, wherein the electrically conductive metal nanowires occupy between 0.5% by volume to 5% by volume of said fabric, wherein the electrically conductive metal nanowires and the synthetic nanofibers are homogenously distributed within the electrically conductive non-woven fabric.

Abstract: Recombinant host cells are provided. The cell genome contains heterologous gene expression cassettes capable of being expressed in the host cell, where the gene expression cassettes encode a nucleic acid sequence encompassing at least 80% of the full-length sequence of the mamAB operon, the mamGDFC operon, and the tmms6 operon of a magnetotactic alphaproteobacterium, respectively. The cells may further comprise gene expression cassettes capable of being expressed in the host cell, where the gene expression cassettes encode a nucleic acid sequence encompassing at least 80% of the full-length sequence of the mamXY operon and/or the feoABI operon of a magnetotactic alphaproteobacterium; where the recombinant host cell, upon expression of the gene expression cassettes in their entirety, is capable of producing magnetic nanoparticles. Preferably, the recombinant host cell is derived from Rhodospirillum rubrum. Methods of producing these recombinant host cells by genetic transposition are provided.

Abstract: The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.

Abstract: A new azobenzene-based fluorescence quencher with excellent solubility in aqueous solution is described here. This compound represents an optimized alternative to dabcyl in a variety of biomolecular applications, like fluorogenic protease substrates or nucleic acids probes.

Abstract: The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer.

Abstract: An identification label with a three-dimensional wrinkled structure may be formed by depositing a hard film with a high elastic modulus on an elongated substrate of a lower elastic modulus. Wrinkles with defects develop as the substrate is subsequently allowed to relax. Defects such as ridge endings and ridge bifurcations are randomly distributed over the wrinkled surface, and allow to uniquely identify any given identification label with the high degree of accuracy. Since the formation of defects is a random process, the wrinkled structure cannot be reproduced or counterfeited. The labels are thus forgery-proof.

Abstract: The present invention relates to the use of an esterase for monitoring and/or tracking the synthesis of a protein, polypeptide or peptide in a cell-free translation system or in an in vivo expression system in which the synthesis of a protein, polypeptide or peptide can occur, wherein said monitoring and/or tracking comprises the detection of the function of said esterase. The present invention further relates to a vector comprising a nucleic acid molecule coding for an esterase and expressing an esterase fusionprotein. Moreover, the present invention relates to a vector comprising a nucleic acid molecule coding for an esterase and comprising in frame at least one multiple cloning site for a further protein/polypeptide/peptide, to be expressed in form of a fusion protein comprising said esterase (esterase activity) and said further proteinaceous peptide structure. The present invention also provides for a protein, polypeptide or peptide encoded by the vectors of the present invention.